- Global Pharma News & Resources

Rising Need For Transplantation Expected To Boost The Global Organ Transplant Immunosuppressant Drugs Market Growth

As per the report, the valuation of global organ transplant immunosuppressant drugs market in 2018 was around USD 4.51 billion and is proceed to produce revenue of about USD 5.79 billion by 2025, boosting at a CAGR of about 3.7% between 2019 and 2025.

Organ transplantation is a curative process to substitute a damaged or missing organ by taking it out from the donor and introducing it in to the recipient’s body. The transplantation can be performed either when the recipient and donor are at the same places or the organs are shipped from the location of the donor to the recipient. So far, effective transplantation has been carried out for the liver, kidneys, lungs, heart, thymus, intestine, and pancreas. Organ transplant immunosuppressant drugs are the type of drugs that are given to decrease the odds of organ rejection following transplantation.

The major factors contributing to the growth of the global organ transplant immunosuppressant drugs market include the rising need for transplantation and the improvement in technologies in tissue engineering & organ transplants. Further, the rising spending by the government on healthcare infrastructure and facilities are anticipated to boost the growth of global market during the forecast period. In addition, the rising patient pool needing organ transplantations and the growing authorization of novel products are also projected to drive the market expansion in coming period. Moreover, elevated expenditure made by several companies and manufacturers for the development of new drugs that can aid efficient treatment will also fuel the growth of the global organ transplant immunosuppressant drugs market. Nonetheless, the elevated price of transplantation and insufficient or inadequate obtainability of organ donors are factors projected to hamper the expansion of the global organ transplant immunosuppressant drugs market to some extent.

Get Sample of this Report

The global organ transplant immunosuppressant drugs market is bifurcated on the basis of drug class, transplant type, and region. The market, on the basis of drug class, is divided into antibodies, steroids, calcineurin inhibitors, mTOR inhibitor, and antiproliferative agents. From these, during the forecast period, the highest share in the market is anticipated to be held by the calcineurin inhibitors segment. The market, on the basis of transplant type, is classified into kidney, pancreas, lung, heart, liver, and others. Among these, kidney segment captured the maximum share in the transplant type segment and is projected to maintain its top pace during the forecast period. The segmental expansion can be credited to the rising need and comparatively better organ obtainability compared to other transplant types. In addition, kidney transplants are deemed to be more reasonably priced compared to the prolonged dialysis periods. The global organ transplant immunosuppressant drugs market, on the basis of distribution channel, is bifurcated into online pharmacies, hospital pharmacies, and retail pharmacies.

Regionally, North America is anticipated to capture the highest share of the global organ transplant immunosuppressant drugs during the forecast period. This expansion can be attributed to the growth in healthcare spending, the advent of healthcare reimbursement policies, the establishment of R&D infrastructure, and a rise in need for organ transplants. Also, Europe market is anticipated to witness a lucrative growth during the coming period. Further, the Asia Pacific market is expected to observe substantial growth owing to the rising revenue generation from the drug classes. In addition, the rising implementation of reimbursement policies and growing spending by respective manufacturers and governments in the healthcare domain are other key factors expected to drive the regional expansion.

The major players within the global organ transplant immunosuppressant drugs market include Sanofi Genzyme, Astellas Pharma, Inc., Novartis AG, Accord Healthcare Ltd., Dr. Reddy’s Laboratories Ltd., Mylan Laboratories, Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Veloxis Pharmaceuticals A/S.

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 11-Aug-2020